SCHEMBL17727554

SCHEMBL17727554

C[C](C)C(=O)NC1CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL221844 0.87 NPC1 (0.73)
SCHEMBL3753914 0.83
SCHEMBL6857874 0.82 SMN1; SMN2 (0.72)
SCHEMBL8032537 0.79 SMN1; SMN2 (0.48)
SCHEMBL368410 0.79
SCHEMBL50350 0.77
SCHEMBL284319 0.77 ATM (0.56)
SCHEMBL284342 0.77 ATM (0.56)
SCHEMBL284318 0.77 ATM (0.56)
SCHEMBL15255710 0.76 SMN1; SMN2 (0.56)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11851449-B2 Heterocyclic amide compounds having an RORvt inhibitory action TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-12-26 US disclosed
EP-3018123-B1 AMIDE COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2023-05-10 EP disclosed
US-20210277030-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-09-09 US disclosed
US-11053262-B2 Heterocyclic amide compounds having RORyT inhibitory action TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-07-06 US disclosed
US-10472376-B2 Amide compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-11-12 US disclosed
US-20170107240-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-04-20 US disclosed
EP-3018123-A1 AMIDE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2016-05-11 EP disclosed